Uterine volume, menstrual patterns, and contraceptive outcomes in users of the levonorgestrel-releasing intrauterine system: A cohort study with a five-year follow-up
article
OA: closed
CC0
⤵ 3 in-corpus citations
AI-generated summary
This five-year cohort study investigated uterine volume, menstrual patterns, and contraceptive outcomes in women using a levonorgestrel-releasing intrauterine system.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
OBJECTIVE: The aim of our study was to evaluate the effects of the LNG-IUS on uterine volume, bleeding patterns, and LNG-IUS-related outcomes among women using the device to treat abnormal uterine bleeding caused by fibroids, adenomyosis, HMB (without structural cause), or contraception.
STUDY DESIGN: This was a 5-year cohort study with LNG-IUS users. We selected 147 women, who were allocated to four groups: a) control (contraception indication); b) fibroids; c) adenomyosis; d) HMB. The visits for clinical and ultrasound evaluations were made at baseline and at 3, 6, 12, 24, 36, 48, and 60 months postinsertion. All data are expressed as mean and standard deviation (SD) or absolute and relative (%) frequency. Differences among groups were established by using the χ2 (chi-square) test and Fisher's exact tests for categorical outcomes, as well as the Mann-Whitney and the Kruskal-Wallis tests and Friedman's ANOVA for continuous variables. We used the 5% significance level as an indication of statistical significance. Logistic regression analyses were performed to study the association between predictors and outcomes. Results are expressed as odds ratios (ORs) with a 95% confidence interval (CI 95%).
RESULTS: Although all groups had real rates of bleeding patterns, troublesome bleeding appeared to be more frequent in the fibroid group (∼15%). Also, along the 60 months of follow-up, uterine volume slightly decreased in the groups of HMB, adenomyosis, and fibroids, but not in the contraception group. However, the isolated volume of fibroids remained unchanged. In this cohort, we observed high continuation rates among LNG-IUS users. The uterine volume ≥200 cm3 was the main predictor of hysterectomy or IUS expulsion in the adenomyosis and fibroid groups.
CONCLUSION: The LNG-IUS may control uterine menstrual bleeding as well as uterine volume in adenomyosis, fibroids, and HMB. An initial uterine volume smaller than 200 cm3 is an important predictor of adherence to treatment and better outcomes.
My notes (saved in your browser only)
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (55)
- Adenomyosis: A Clinical Review of a Challenging Gynecologic Condition via openalex
- Clinical effects of the levonorgestrel-releasing intrauterine device in patients with adenomyosis via openalex
- Effectiveness of the levonorgestrel-releasing intrauterine system in the treatment of adenomyosis diagnosed and monitored by magnetic resonance imaging via openalex
- Factors affecting the spontaneous expulsion of the levonorgestrel-releasing intrauterine system via openalex
- Levonorgestrel Intrauterine System versus Medical Therapy for Menorrhagia via openalex
- New paradigms in the conservative surgical and interventional management of adenomyosis via openalex
- The LNG-IUS study on adenomyosis: a 3-year follow-up study on the efficacy and side effects of the use of levonorgestrel intrauterine system for the treatment of dysmenorrhea associated with adenomyosis via openalex
- Treatment of symptomatic adenomyosis with the levonorgestrel‐releasing intrauterine system via openalex
- W2015038451 via openalex
- W2030656284 via openalex
- W2032966634 via openalex
- W2040431072 via openalex
- W2045277407 via openalex
- W2046216810 via openalex
- W2046818218 via openalex
- W2057333261 via openalex
- W2075217182 via openalex
- W2080638826 via openalex
- W2084382087 via openalex
- W2084629480 via openalex
- W2085226926 via openalex
- W2089929948 via openalex
- W2090256757 via openalex
- W2090979444 via openalex
- W2121841613 via openalex
- W2140370772 via openalex
- W2155352577 via openalex
- W2164017484 via openalex
- W2199365787 via openalex
- W2770828290 via openalex
- W2804476816 via openalex
- W2897701511 via openalex
- W2979170166 via openalex
- W2987270078 via openalex
- W2996731702 via openalex
- W3022548192 via openalex
- W3034347554 via openalex
- W3035269429 via openalex
- W3091949729 via openalex
- W3107083772 via openalex
- W3124419655 via openalex
- W4245947400 via openalex
- W4299700721 via openalex
- W6610766590 via openalex
- W6673101919 via openalex
- W6687897378 via openalex
- W11896051 via openalex
- W6768890523 via openalex
- W1827097019 via openalex
- W1964671590 via openalex
- W1966300095 via openalex
- W1978438749 via openalex
- W1981564167 via openalex
- W1987461701 via openalex
- W1998419184 via openalex
Cited by (4)
- Clinical efficacy and safety of subtotal resection of adenomyotic lesions based on the Kishi classification: a retrospective case series study 2026
- Assessing the impact of hormonal contraceptive use on menstrual health among women of reproductive age - a systematic review 2024
- Association between uterine leiomyoma and fragmented QRS waves: a prospective case-control study. 2024
- Efficacy of etonogestrel subcutaneous implants versus the levonorgestrel-releasing intrauterine system in the conservative treatment of adenomyosis 2024
Source provenance
- europepmc
- last seen: 2026-06-17T06:13:18.893374+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-06-17T06:13:08.235974+00:00
License: CC0
· commercial use OK